Product Program year 2019 Source: CMS Open Payments

Ajovy

Drug Central Nervous System

NDC 51759-204-10

Open in the dashboard

General payments

$5,327,145

64,521 payments

Research payments

$2,446,170

770 payments

Through program year 2019, $5,327,145 in general payments and $2,446,170 in research payments were reported against Ajovy (Central Nervous System).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $5,327,145 64,521
2019 Research $2,446,170 770

Breakdown

Who paid General payments · program year 2019
  1. Teva Pharmaceuticals USA, Inc. $5,327,145 64,521 payments
Top recipients General payments · program year 2019
  1. Andrew Blumenfeld Neurology · Carlsbad, CA $158,547 3% · 169 payments
  2. Jack Schim Neurology · Carlsbad, CA $125,347 2% · 169 payments
  3. Egilius Spierings Neurology · Wellesley Hills, MA $97,499 2% · 96 payments
  4. Santiago Restrepo Neurology · San Antonio, TX $63,533 1% · 173 payments
  5. Stephen Silberstein Neurology · Philadelphia, PA $57,563 1% · 41 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Neurology Psychiatry & Neurology $3,979,337 78% · 3,488 practitioners
  2. Family Medicine $374,419 7% · 6,144 practitioners
  3. Internal Medicine $261,787 5% · 3,359 practitioners
  4. Interventional Pain Medicine Pain Medicine $74,481 1% · 361 practitioners
  5. Clinical Neurophysiology Psychiatry & Neurology $50,349 <1% · 70 practitioners

The top 5 of 140 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. California $739,780 14% · 1,669 recipients
  2. New York $439,967 8% · 955 recipients
  3. Texas $420,052 8% · 1,566 recipients
  4. Pennsylvania $330,854 6% · 820 recipients
  5. Illinois $278,425 5% · 366 recipients

The top 5 of 56 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

79,571

Prescriptions dispensed, refills included

Drug cost

$66,251,478

Paid at the pharmacy, in all

Medicare Part D drugs matched to Ajovy, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Ajovy Autoinjector Fremanezumab-Vfrm Similar name 2,538 66,422 $55,602,588
Ajovy Syringe Fremanezumab-Vfrm Similar name 813 13,149 $10,648,891

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 186 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Robert Pearlman Neurology AL 409 $294,924 None on record
Michael Zatt Neurology OR 364 $171,673 No profile
Jessica Bussey Nurse Practitioner OH 259 $272,681 None on record
Lisa Wall Nurse Practitioner OR 247 $114,207 No profile
Afshin Mohammadi Neurology OH 223 $100,197 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 186 with Patron
64,521 general · 770 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record